sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
|
Zidovudine
|
probenecid
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s2
|
DDI-DrugBank.d260.s2.p0
|
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
|
antihypertensives
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s10
|
DDI-DrugBank.d114.s10.p20
|
Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
|
Acamprosate
|
antidepressants
|
EFFECT
|
Acamprosate_ddi.xml
|
DDI-DrugBank.d0.s6
|
DDI-DrugBank.d0.s6.p0
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
perphenazine
|
phenytoin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p144
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
monoamine oxidase inhibitors
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p16
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
azole antifungal agents
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p21
|
Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
|
Estrogen
|
ARIMIDEX
|
ADVISE
|
Anastrozole_ddi.xml
|
DDI-DrugBank.d195.s9
|
DDI-DrugBank.d195.s9.p0
|
Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
|
Tadalafil
|
indinavir
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s90
|
DDI-DrugBank.d97.s90.p0
|
As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
|
INDOCIN
|
lithium
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s18
|
DDI-DrugBank.d82.s18.p0
|
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
|
FACTIVE
|
contraceptive
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s1
|
DDI-DrugBank.d347.s1.p5
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
phenytoin
|
corticosteroids
|
MECHANISM
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p5
|
Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
|
spironolactone
|
potassium
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s4
|
DDI-DrugBank.d176.s4.p6
|
Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
|
flurbiprofen
|
hypoglycemic agents
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s19
|
DDI-DrugBank.d529.s19.p0
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
theophylline
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p8
|
Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
|
Itraconazole
|
quinidine
|
EFFECT
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s28
|
DDI-DrugBank.d165.s28.p0
|
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
|
ouabain
|
droperidol
|
EFFECT
|
1167743.xml
|
DDI-MedLine.d23.s2
|
DDI-MedLine.d23.s2.p2
|
Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
|
ergotamine
|
antibiotics
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s6
|
DDI-DrugBank.d410.s6.p0
|
apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
|
diphenidol
|
apomorphine
|
EFFECT
|
Diphenidol_ddi.xml
|
DDI-DrugBank.d120.s2
|
DDI-DrugBank.d120.s2.p4
|
The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
|
tetracycline
|
Penthrane
|
EFFECT
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s5
|
DDI-DrugBank.d500.s5.p0
|
However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
|
retinyl acetate
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s6
|
DDI-MedLine.d12.s6.p0
|
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
|
imatinib
|
Gleevec
|
NONE
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s0
|
DDI-DrugBank.d115.s0.p6
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
cyclosporine
|
valproate
|
NONE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p16
|
As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe reaction and produce false increases in the levels of creatinine reported.
|
cephalosporins
|
cefotetan
|
NONE
|
Cefotetan_ddi.xml
|
DDI-DrugBank.d483.s4
|
DDI-DrugBank.d483.s4.p0
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
tubocurarine
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p10
|
Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
|
fluvoxamine
|
cisapride
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s11
|
DDI-DrugBank.d76.s11.p2
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
danazol
|
diltiazem
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p142
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Kadian
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p33
|
Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
|
oxytocics
|
dinoprost
|
EFFECT
|
Dinoprost Tromethamine_ddi.xml
|
DDI-DrugBank.d181.s0
|
DDI-DrugBank.d181.s0.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
doxycycline
|
nortriptyline
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p582
|
In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
|
labetalol HCl
|
tricyclic antidepressants
|
EFFECT
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s0
|
DDI-DrugBank.d412.s0.p0
|
Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
|
erythromycin
|
cimetidine
|
NONE
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s1
|
DDI-DrugBank.d316.s1.p9
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
MAOI
|
Tricyclic antidepressants
|
NONE
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p29
|
SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
|
5-HT1 agonists
|
SSRIs
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s7
|
DDI-DrugBank.d410.s7.p2
|
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
|
erythromycin
|
dihydroergotamine
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s5
|
DDI-DrugBank.d397.s5.p1
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
phenothiazines
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p1
|
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
|
PROLEUKIN
|
interferon-alfa
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s5
|
DDI-DrugBank.d114.s5.p4
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
epinephrine
|
tricyclic antidepressants
|
EFFECT
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s0
|
DDI-DrugBank.d153.s0.p6
|
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
|
diclofenac
|
salicylic acid
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s18
|
DDI-DrugBank.d249.s18.p0
|
Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
|
carbamazepine
|
escitalopram
|
MECHANISM
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s23
|
DDI-DrugBank.d568.s23.p5
|
Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
|
Anagrelide
|
aspirin
|
EFFECT
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s8
|
DDI-DrugBank.d75.s8.p0
|
Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
|
entecavir
|
tenofovir disoproxil fumarate
|
NONE
|
Entecavir_ddi.xml
|
DDI-DrugBank.d295.s1
|
DDI-DrugBank.d295.s1.p2
|
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
|
steroids
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s3
|
DDI-DrugBank.d284.s3.p13
|
Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
|
primidone
|
AEDs
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s12
|
DDI-DrugBank.d277.s12.p14
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
quinidine
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p7
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
chloral hydrate
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p6
|
Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.
|
efavirenz
|
SUSTIVA
|
NONE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s87
|
DDI-DrugBank.d531.s87.p0
|
Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
|
Valproate
|
valproate
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s7
|
DDI-DrugBank.d277.s7.p1
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
vancomycin
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p7
|
Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
|
buprenorphine
|
benzodiazepines
|
INT
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s3
|
DDI-DrugBank.d380.s3.p0
|
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
|
isoniazid
|
levodopa
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s2
|
DDI-DrugBank.d47.s2.p14
|
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
|
calcium channel blockers
|
organic nitrates
|
EFFECT
|
Isosorbide Mononitrate_ddi.xml
|
DDI-DrugBank.d479.s2
|
DDI-DrugBank.d479.s2.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
PABA
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p8
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
chlorpromazine
|
antiparkinsonian drug
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p5
|
Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
|
dobutamine
|
nitroprusside
|
EFFECT
|
Dobutamine_ddi.xml
|
DDI-DrugBank.d274.s2
|
DDI-DrugBank.d274.s2.p0
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
thiazides
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p3
|
Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
|
Quinolones
|
anticoagulants
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s8
|
DDI-DrugBank.d562.s8.p1
|
However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
|
digoxin
|
FLOLAN
|
MECHANISM
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s5
|
DDI-DrugBank.d241.s5.p1
|
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
|
famotidine
|
dasatinib
|
EFFECT
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s11
|
DDI-DrugBank.d48.s11.p19
|
Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
|
Aspirin
|
nonsteroidal anti-inflammatory
|
ADVISE
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s4
|
DDI-DrugBank.d443.s4.p2
|
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
|
teniposide
|
TAXOL
|
ADVISE
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s11
|
DDI-DrugBank.d288.s11.p2
|
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
|
trovafloxacin
|
opiate
|
MECHANISM
|
11210403.xml
|
DDI-MedLine.d124.s1
|
DDI-MedLine.d124.s1.p1
|
Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
|
Nonsteroidal anti-inflammatory drugs
|
methotrexate
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s17
|
DDI-DrugBank.d132.s17.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
alosetron
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p29
|
In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
|
REVIA
|
opioid
|
EFFECT
|
Naltrexone_ddi.xml
|
DDI-DrugBank.d346.s5
|
DDI-DrugBank.d346.s5.p0
|
Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
|
anakinra
|
HUMIRA
|
EFFECT
|
Adalimumab_ddi.xml
|
DDI-DrugBank.d493.s4
|
DDI-DrugBank.d493.s4.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
pentoxifylline
|
sulfinpyrazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1323
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
anesthetics
|
antihistamines
|
NONE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p62
|
The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
|
glipizide
|
fluconazole
|
MECHANISM
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s13
|
DDI-DrugBank.d225.s13.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
naproxen
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p32
|
INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
|
INH
|
ketoconazole
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s25
|
DDI-DrugBank.d458.s25.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
warfarin sodium
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p53
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
nalidixic acid
|
pentoxifylline
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1235
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
thyroid products
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p10
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
barbiturates
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p2
|
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
|
Mefloquine
|
calcium channel blockers
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s9
|
DDI-DrugBank.d220.s9.p2
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
retinyl acetate
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p7
|
Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
|
Heparin Sodium
|
heparin
|
NONE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s7
|
DDI-DrugBank.d488.s7.p4
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
dapsone
|
ribavirin
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p52
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clobazam
|
methadone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p311
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
Acetaminophen
|
nortriptyline
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p71
|
In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
|
propranolol
|
captopril
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s11
|
DDI-DrugBank.d460.s11.p11
|
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
|
TORADOL
|
thiothixene
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s19
|
DDI-DrugBank.d3.s19.p7
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
blood thinner
|
Tegretol
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p5
|
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
|
prednisone
|
clarithromycin
|
NONE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s1
|
DDI-DrugBank.d431.s1.p50
|
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
|
beta-adrenoceptor blocking agents
|
INDOCIN
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s33
|
DDI-DrugBank.d82.s33.p1
|
Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
|
adenosine
|
dipyridamole
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s7
|
DDI-DrugBank.d226.s7.p0
|
therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
|
anticoagulant
|
Tagamet
|
ADVISE
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s2
|
DDI-DrugBank.d171.s2.p0
|
Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
|
alcohol
|
vitamin B12
|
MECHANISM
|
Cyanocobalamin_ddi.xml
|
DDI-DrugBank.d39.s1
|
DDI-DrugBank.d39.s1.p5
|
Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
|
warfarin
|
tolbutamide
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s12
|
DDI-DrugBank.d460.s12.p24
|
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
|
alprazolam
|
paroxetine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s9
|
DDI-DrugBank.d131.s9.p4
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
alcohol
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p2
|
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
|
BREVIBLOC
|
morphine
|
ADVISE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s10
|
DDI-DrugBank.d422.s10.p1
|
In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.
|
BROVANA
|
theophylline
|
NONE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s9
|
DDI-DrugBank.d284.s9.p2
|
Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
|
L-glutamine
|
indomethacin
|
EFFECT
|
L-Glutamine_ddi.xml
|
DDI-DrugBank.d66.s2
|
DDI-DrugBank.d66.s2.p3
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
propoxyphene
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p19
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
antipsychotics
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p4
|
Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
|
nadolol
|
timolol
|
NONE
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s5
|
DDI-DrugBank.d507.s5.p3
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
lincomycin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p6
|
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
|
doxorubicin
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s2
|
DDI-DrugBank.d114.s2.p17
|
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
|
STRATTERA
|
paroxetine
|
ADVISE
|
Atomoxetine_ddi.xml
|
DDI-DrugBank.d11.s3
|
DDI-DrugBank.d11.s3.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.